ITEMS IN AFP WITH KEYWORD:
Combination oral contraceptive pills (OCPs) are an excellent treatment option for women desiring medical therapy for hirsutism. Based on this meta-analysis, an accompanying practice guideline recommends adding an antiandrogen, such as finasteride (Propecia), if there is an inadequate response within six months.
Jan 1, 2019 Issue
Deprescribing Benzodiazepine Receptor Agonists for Insomnia in Adults [Practice Guidelines]
A multidisciplinary group of clinicians as part of the Deprescribing Guidelines in the Elderly project has developed evidence-based guidelines focused on deprescribing long-term Benzodiazepine receptor agonists (BZRAs) in patients taking them for insomnia, with the goal of helping physicians and patients make appropriate decisions about BZRA use.
Oct 1, 2018 Issue
Hormone Therapy for Primary Prevention of Cardiovascular Disease in Postmenopausal Women [Medicine by the Numbers]
No benefit was observed in postmenopausal women receiving hormone therapy for primary prevention of cardiovascular disease. Find out more.
Long-term hormone therapy decreased the risk of all fractures, including hip and vertebral fractures. However, the risks far outweighed the benefits of this intervention.
Jul 1, 2018 Issue
Procalcitonin to Guide Antibiotic Therapy in Acute Respiratory Infections [Cochrane for Clinicians]
Procalcitonin-guided antibiotic therapy, when compared with routine treatments, results in decreased mortality in patients with acute respiratory infections (absolute risk reduction [ARR] = 1.4%; number needed to treat [NNT] = 71).
Just about every time someone asks, “Can I get away with a shorter course of antibiotics,” the answer is, “Yes, you can.” Shorter courses reduce cost and may reduce the likelihood of adverse events.
A short course of oral corticosteroids is appropriate for many patients with specific conditions. However, widespread use of corticosteroids in patients with non-pneumonia lower respiratory tract infection, nonsevere sore throat, or low back pain is inappropriate and not worth the risk of rare but potentially serious harms.
We want to assure all stakeholders of the rigorous approval process that supports the FDA's commitment to ensuring the high quality of generic drugs marketed in the United States.
Apr 15, 2018 Issue
Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women [Putting Prevention into Practice]
D.M. is a 52-year-old woman who presents to your office for a well-woman visit. She has been menopausal since 50 years of age and has no significant medical or surgical history. She is up to date on her recommended screenings, with normal mammography and colonoscopy results, and has no history of an...
Apr 15, 2018 Issue
Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Recommendation Statement [U.S. Preventive Services Task Force]
The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal women and the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal women who have had a hysterectomy.